Search

Caffeine

[A187691,L9851] It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. … [T716] Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.

Xylose

Nevertheless, xylose by itself may not necessarily serve many purposes immediately - but its metabolism results in a variety of substrates that can serve important nutritional and biological purposes. … The levorotary form, L-xylose, can refer to the form that is synthesized.

Ephedra sinica stem

Tradipitant

[A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion. … Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors.

Ecamsule

Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal. … Ecamsule is an organic compound which is added to many sunscreens to filter out UVA rays. It is a benzylidene camphor derivative, many of which are known for their excellent photostability.

Axicabtagene ciloleucel

[L40054] The development of resulted from early preclinical studies conducted by a group of researchers at the National Cancer Institute (NCI), who demonstrated that T cells expressing an anti-CD19 CAR … can produce cytokines that efficiently kill leukemic cells _in vitro_.

Opium

This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. … [A32175] Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered.

Dorzolamide

[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. … [A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.

Respiratory syncytial virus vaccine, adjuvanted

Arexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals. … [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]